Who founded Lipidiopharma?

Lipidiopharma was founded by James Mackay in 2019.

Who are Lipidiopharma's investors?

Lipidiopharma's investors include 3E Bioventures Capital.

How much funding has Lipidiopharma raised?

Lipidiopharma has disclosed $4.6M raised across 1 round.

Where is Lipidiopharma headquartered?

Lipidiopharma is headquartered in San Diego, US.

Lipidiopharma

San Diego, US · Founded 2019 · 1 known investors

Lipidio Pharma is a drug development company that acquires molecules with unrealized therapeutic potential and advances them through preclinical and clinical development toward approval or exit. It is currently developing therapeutics for two indications, obesity and sebaceous hyperplasia.

Biotech Healthtech

Founders & leadership

Lipidiopharma was founded in 2019 by James Mackay.

James MackayCo-Founder

David BulloughNamed on SEC filing

Daniel PetreeNamed on SEC filing

J. Gordon FoulkesNamed on SEC filing

Investors · 1

3E Bioventures CapitalPalo Alto

Reported raises · per SEC filings

Form D private placements

$4.6M disclosed across 1 round · 2019

▶$4.6MraisedNov 2019 · 58 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

David BulloughDirector
Daniel PetreeDirector
J. Gordon FoulkesExecutive Officer, Director

Offering amount: $12M
Amount sold: $4.6M
Sales commissions: $462.3K
Placement agents: Maxim Group LLC
First sale: Nov 2019
Incorporated: Corporation, Delaware, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 7

by search overlap

Adipopharma5 shared keywordsAdipoPharma is a French biotech company developing PATAS, a first-in-class stapled peptide insulin sensitizer that targets adipocytes to treat insulin resistance, type 2 diabetes, and associated comorbidities. Its adipocyte-focused approach aims to address the root cause of type 2 diabetes, with its lead drug entering clinical trials in 2025.

Novo Nordisk4 shared keywordsNovo Nordisk is a pharmaceutical company that develops and markets treatments for conditions including diabetes, obesity/weight management, and haemophilia, with products such as GLP-1 therapies. It serves patients and healthcare markets globally.

Bioworld4 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Radiuspharm3 shared keywordsRadius is a biopharmaceutical company focused on bone health and related therapeutic areas for underserved patient populations. It markets commercial products in the U.S., including TYMLOS (abaloparatide) injection and BINOSTO (alendronate sodium).

Ligand3 shared keywordsLigand is a royalty aggregator that provides strategic capital to biopharmaceutical companies to finance and advance late-stage clinical development programs. It manages a diversified portfolio of over 200 commercial, clinical, and preclinical-stage biopharmaceutical royalty assets across multiple therapeutic areas.

Diasome3 shared keywordsDiasome develops the Hepatocyte-Directed Vesicle (HDV) platform to deliver drugs to the liver's portal-hepatic region for improved metabolic control. The company is advancing therapies for diabetes, obesity, and cardiometabolic diseases by targeting hepatocytes rather than peripheral tissues.

Parabilis Medicines3 shared keywordsHelicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules. The platform uses AI and simulation to engineer helical peptides with non-canonical amino acids for precision binding across a range of therapeutic applications.

Companies competing with Lipidiopharma for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Lipidiopharma do?: Lipidio Pharma is a drug development company that acquires molecules with unrealized therapeutic potential and advances them through preclinical and clinical development toward approval or exit. It is currently developing therapeutics for two indications, obesity and sebaceous hyperplasia.
Who founded Lipidiopharma?: Lipidiopharma was founded by James Mackay in 2019.
Who are Lipidiopharma's investors?: Lipidiopharma's investors include 3E Bioventures Capital.
How much funding has Lipidiopharma raised?: Lipidiopharma has disclosed $4.6M raised across 1 round.
Where is Lipidiopharma headquartered?: Lipidiopharma is headquartered in San Diego, US.